In a comprehensive Genomic Press Interview, Dr. Kerry Ressler, Chief Scientific Officer at McLean Hospital and Professor of Psychiatry at Harvard Medical School, unveils groundbreaking advances in understanding the neurobiological basis of post-traumatic stress disorder (PTSD) and related anxiety conditions.
Zealand drug hit with CRL for ultra-rare disease amid manufacturing concerns, plans to resubmit in 2024
The FDA rejected Zealand Pharma’s glucagon receptor agonist in congenital hyperinsulinism (CHI) after identifying problems at a third-party manufacturing site. The company said it remains